US2016024206A1PendingUtilityA1

Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma

51
Assignee: INST NAT SANTE RECH MEDPriority: Dec 18, 2008Filed: Oct 7, 2015Published: Jan 28, 2016
Est. expiryDec 18, 2028(~2.4 yrs left)· nominal 20-yr term from priority
Inventors:Patricia ForgezMarco Alifano
A61K 38/482A61P 35/00C12Q 2600/118C12Q 1/6886G01N 2410/00C12Y 304/21039C07K 16/26C12Q 2600/158G01N 2333/726A61K 38/4813A61K 31/4709C12Y 304/17001G01N 2800/56C07K 16/3023C12Y 304/24016C07K 2317/76A61K 38/4886G01N 33/57557G01N 33/57407
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.

Claims

exact text as granted — not AI-modified
1 . A method of determining the prognosis of a subject suffering from malignant pleural mesothelioma, comprising the step of detecting the expression of neurotensin (NTS) in a mesothelioma sample obtained from said subject. 
     
     
         2 . A method for the treatment of malignant pleural mesothelioma, wherein an inhibitor of the neurotensin activation of neurotensin receptor 1 (NTSR1) is administered to a subject in need thereof. 
     
     
         3 . The method of  claim 2 , wherein said inhibitor of the neurotensin activation of NTSR1 is an agent down-regulating the expression of neurotensin or of NTSR1. 
     
     
         4 . The method of  claim 2 , wherein said inhibitor of the neurotensin activation of NTSR1 is selected from the group consisting of an antibody against neurotensin, a fragment thereof which binds to neurotensin, an antibody against the neurotensin receptor 1 and a fragment thereof which binds to the neurotensin receptor 1. 
     
     
         5 . The method of  claim 2 , wherein said inhibitor of the neurotensin activation of NTSR1 is an antagonist of NTSR1. 
     
     
         6 . The method of  claim 2 , wherein said inhibitor of the neurotensin activation of NTSR1 is a protease that can degrade neurotensin. 
     
     
         7 . A method for the treatment of malignant pleural mesothelioma, wherein a cytotoxic agent which binds to NTSR1 is administered to a subject in need thereof.

Join the waitlist — get patent alerts

Track US2016024206A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.